No-vote letter update, page-71

Well said TT. Your following statement says it all.

”

• The quarterly cash flow statements shows that the company is facing serious headwinds with ResappDx, and the existing partnerships are not translating into positive cash flow. Cash flow will be critical to ResApp going forward, and ResApp is just not showing any signs that it can generate it.
• In spite of the company’s ongoing work on the Covid-19 test they have not been able to announce any significant improvement in the prediction rate through adjusting (tweaking) the algorithm. The clear implication is that the Covid-19 test is sensitive to variants and will have to be retrained with new clinical data each time a new variant becomes dominant. Each release of the Covid-19 test is therefore likely to be short-lived and there will be limited opportunity to recover the costs of obtaining fresh clinical training data.”

How do holders think the share price could possibly be worth much more than it is now?
Held RAP for years and have followed it for years….even thought about getting back in again but nothing BIG enough happened to persuade me.

The luckiest folk to have held would be the first investors that bought at 1.7c or there about to 50c roughly.
Unless of course they rode it all the way back Down.
If you all have so much confidence in what RAP have produced then buy some Pfizer shares….it will surely have better management to carry on the work.